Work

First Report of Trametinib‐Nintedanib Combination in KRAS G12D ‐Mutated Pancreatic Cancer: Efficacy and Fatal Hemorrhagic Complication: A Case Report

Year: 2025

Type: article

Abstract: This is the first report of trametinib-nintedanib for a 57-year-old KRAS G12D-mutated recurrent pancreatic ductal adenocarcinoma. He had transient remission (lower CA19-9, stable lesions) but died of gastrointestinal bleeding, showing efficacy and bleeding risk.

Source: Clinical Case Reports

DOI: 10.1002/ccr3.71505

Authors: Yufei Zhao, Li Yuan, Song Wang, Chensi Wu

Institutions: Hebei Medical University, Fourth Hospital of Hebei Medical University

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,820